

**Date and Time:** 24<sup>th</sup> May 2013 10:00-16:00

**Minutes:** Confirmed

**Multiple Sclerosis GDG Meeting 7**

**Place:** Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London, W1W 5QZ

**Present:** GDG

1. Paul Cooper	PC
2. Jeremy Chataway	JC
3. Peter Brex	PB
4. David Kernick	DK
5. Wendy Hendrie	WH
6. Susan Hourihan	SH
7. Pamela Bostock	PB
8. Noreen Barker	NB
9. Richard Warner	RW
10. Aleks de Gromoboy	ADG
11. Ann Hodgson	AH
12. Emma Rowe	ER

NCGC Technical team

13. Sharon Swain	SS
14. Mark Perry	MP
15. Amy Kelsey	AK
16. Sophia Winterbourne	SW
17. Krishna Chinthapalli	KC
18. Betta Fenu (for points 5-8)	BF
19. Lina Gulhane (for point 8)	LG
20. Gill Ritchie	GR

NICE:

1. Jaimella Espley	JE
--------------------	----

Apologies

1. Norma O'Flynn	NOF
------------------	-----

## Notes

1. The Chair welcomed the group to the Multiple Sclerosis Guideline Development Group (GDG) meeting 7. Apologies were received from Norma O'Flynn. The Chair introduced Gill Ritchie, NCGC Operations Director, to the group, who attended the meeting on behalf of NOF. He also introduced Sophia Winterbourne, NCGC Health Economist who is taking over from Betta.
2. The Chair asked the GDG to declare any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests

Peter Brex declared the following personal pecuniary interest: he took part in a debate at an MS nurse meeting for which he received an honorarium. He also declared the following non-personal pecuniary interest: he gave a lecture on mental health in MS at a meeting sponsored by Merck-Serono for which a payment was made to Kings College Hospital charitable trust.

Noreen Barker declared the following personal pecuniary interest: she attended a regional MS professionals meeting that was sponsored by Biogen Idec (room and lunch).

Richard Warner declared the following personal pecuniary interest: he sat on an advisory board on relapse management for Novartis. The GDG agreed that as this was a potential conflict of interest, Richard would leave the meeting room when reviewing the pharmacological recommendations.

Pam Bostock declared the following personal pecuniary interest: she attended MS society fatigue management (FACETS) course in May 2013 which was funded by the MS society.

All other GDG members had no change in their previous declarations.

3. The Chair introduced Mark Perry, NCGC Research Fellow, who presented the clinical evidence review of the interventions that improve coordination of care for adults with MS and their carers. The GDG discussed the evidence presented. The Chair thanked MP for his presentation.
4. The Chair introduced Sophia Winterbourne, NCGC Health Economist, who presented the health economic evidence review of the interventions that improve coordination of care for adults with MS and their carers. The GDG discussed the evidence presented and developed draft recommendations. The Chair thanked SW for her presentation.
5. The Chair introduced Jaimella Espley, NICE Senior Medical Editor, who lead the review of the current draft recommendations. The Chair thanked JE for her presentation.
6. The Chair introduced Amy Kelsey, NCGC Project Manager, who presented the draft guideline chapter structure to the GDG.
7. MP then gave a presentation to the GDG on the guideline research recommendations process and those already identified by the GDG during development so far. The Chair thanked MP for his presentation.
8. MP then led discussion with the GDG on the research protocol for 1 clinical question. The

## Notes

following research protocol was discussed and by the group:

- For adults with MS, what is the clinical evidence and cost effectiveness of the non-pharmacological management of memory and cognitive problems with neuropsychological rehabilitation?

AOB

9. PC informed the group that he had been approached by NICE to comment on whether or not an evidence review of Low Dose Naltrexone should be carried out. The GDG discussed and supported this decision.
10. AK confirmed the remaining GDG dates with the group.
11. There was no other AOB. The Chair closed the meeting and thanked everyone for attending.

## Date, time and venue of the next meeting

12. 27<sup>th</sup> June 2013, 10:00-16:00, Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London, W1W 5QZ